Halozyme Therapeutics revenue was $267.59 m in FY, 2020 which is a 36.5% year over year increase from the previous period.
Halozyme Therapeutics revenue breakdown by business segment: 33.1% from Royalties, 46.0% from Revenues under Collaborative Agreements and 20.9% from Product Sales
Halozyme Therapeutics revenue breakdown by geographic segment: 40.0% from United States, 7.5% from Belgium, 35.9% from Switzerland, 11.4% from Ireland and 5.3% from Other
USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|
Revenue | 151.9m | 196.0m | 267.6m |
Revenue growth, % | 29% | 37% | |
Cost of goods sold | 10.1m | 45.5m | 43.4m |
Gross profit | 141.7m | 150.4m | 224.2m |
Gross profit Margin, % | 93% | 77% | 84% |
R&D expense | 150.3m | 140.8m | 34.2m |
General and administrative expense | 60.8m | 77.3m | 45.7m |
Operating expense total | 211.1m | 218.1m | 80.0m |
EBIT | (69.3m) | (67.6m) | 144.3m |
EBIT margin, % | (46%) | (34%) | 54% |
Interest expense | 18.0m | 11.6m | 20.4m |
Pre tax profit | (79.8m) | (72.3m) | 129.3m |
Income tax expense | 537.0k | (11.0k) | 217.0k |
Net Income | (80.3m) | (72.2m) | 129.1m |
EPS | (0.6) | (0.5) | 0.9 |
USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|
Revenue | 56.9m | 39.1m | 46.2m | 25.4m | 55.2m | 65.3m | 89.0m |
Cost of goods sold | 4.6m | 1.9m | 22.3m | 5.8m | 5.7m | 5.6m | 18.2m |
Gross profit | 52.3m | 37.3m | 23.9m | 19.6m | 49.5m | 59.7m | 70.8m |
Gross profit Margin, % | 92% | 95% | 52% | 77% | 90% | 91% | 80% |
R&D expense | 31.3m | 33.9m | 30.5m | 10.2m | 9.0m | 7.7m | 9.0m |
General and administrative expense | 18.0m | 17.3m | 18.0m | 12.6m | 11.0m | 11.7m | 11.1m |
Operating expense total | 49.3m | 51.2m | 48.4m | 22.8m | 19.9m | 19.4m | 20.1m |
EBIT | 3.0m | (14.0m) | (24.5m) | (3.2m) | 29.6m | 40.3m | 50.7m |
EBIT margin, % | 5% | (36%) | (53%) | (13%) | 54% | 62% | 57% |
Interest expense | 3.2m | 2.6m | 2.1m | 5.3m | 5.0m | 5.0m | 2.0m |
Pre tax profit | 1.8m | (14.6m) | (25.0m) | (6.1m) | 25.9m | 36.3m | 28.1m |
Income tax expense | 22.0k | 17.0k | 13.0k | 11.0k | 58.0k | 63.0k | 191.0k |
Net Income | 1.8m | (14.6m) | (25.0m) | (6.1m) | 25.8m | 36.2m | 27.9m |
EPS | 0.0 | (0.1) | (0.2) | 0.0 | 0.2 | 0.3 | 0.2 |
USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|
Cash | 57.9m | 120.2m | 147.7m |
Accounts Receivable | 30.0m | 59.4m | 97.7m |
Prepaid Expenses | 20.7m | 33.4m | 28.3m |
Inventories | 22.6m | 29.4m | 60.7m |
Current Assets | 427.8m | 543.4m | 554.8m |
PP&E | 7.5m | 10.9m | 10.6m |
Total Assets | 440.2m | 565.9m | 579.9m |
Accounts Payable | 4.1m | 6.4m | 1.9m |
Short-term debt | 91.5m | 19.5m | 397.2m |
Current Liabilities | 149.4m | 85.6m | 421.4m |
Long-term debt | 34.9m | 383.0m | |
Total Debt | 126.4m | 402.6m | 397.2m |
Common Stock | 145.0k | 137.0k | 135.0k |
Additional Paid-in Capital | 780.5m | 695.1m | 625.5m |
Retained Earnings | (531.4m) | (603.7m) | (474.6m) |
Total Equity | 248.9m | 91.8m | 151.0m |
Debt to Equity Ratio | 0.5 x | 4.4 x | 2.6 x |
Debt to Assets Ratio | 0.3 x | 0.7 x | 0.7 x |
Financial Leverage | 1.8 x | 6.2 x | 3.8 x |
USD | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|
Net Income | (80.3m) | (72.2m) | 129.1m |
Depreciation and Amortization | 2.4m | 4.1m | 3.3m |
Accounts Receivable | 11.6m | (29.4m) | (38.3m) |
Inventories | (17.5m) | (6.7m) | (31.4m) |
Accounts Payable | 5.7m | 4.6m | (41.2m) |
Cash From Operating Activities | (49.5m) | (85.4m) | 55.5m |
Purchases of PP&E | (4.7m) | (4.0m) | (2.5m) |
Cash From Investing Activities | 2.5m | (5.5m) | 78.4m |
Long-term Borrowings | (77.5m) | (108.1m) | (19.6m) |
Cash From Financing Activities | (63.8m) | 153.2m | (106.3m) |
Net Change in Cash | (110.8m) | 62.2m | 27.5m |
Interest Paid | 16.9m | 9.0m | 6.5m |
Income Taxes Paid | 220.0k | 188.0k | 180.0k |
USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|
Net Income | 1.8m | (12.8m) | (37.8m) | (6.1m) | 19.7m | 55.9m | 27.9m |
Depreciation and Amortization | 990.0k | 2.0m | 3.0m | 857.0k | 1.7m | 2.5m | 738.0k |
Accounts Receivable | 1.8m | (2.2m) | (10.7m) | 29.7m | 22.0m | (3.1m) | 9.3m |
Inventories | (8.6m) | (21.3m) | (13.4m) | (12.1m) | (18.9m) | (28.3m) | 2.5m |
Accounts Payable | (7.9m) | 1.7m | (6.8m) | (27.6m) | (37.5m) | (40.1m) | (6.6m) |
Cash From Operating Activities | (4.4m) | (29.2m) | (58.8m) | (4.8m) | (1.5m) | 4.5m | 58.3m |
Purchases of PP&E | (927.0k) | (2.3m) | (3.4m) | (114.0k) | (629.0k) | (805.0k) | (270.0k) |
Cash From Investing Activities | 28.8m | 76.3m | 117.3m | 38.1m | 50.0m | 19.9m | (45.2m) |
Long-term Borrowings | (21.3m) | (42.0m) | (63.3m) | (16.7m) | (19.6m) | (19.6m) | (369.1m) |
Cash From Financing Activities | (21.7m) | (38.0m) | (57.2m) | (48.6m) | (35.0m) | (78.9m) | 338.7m |
Net Change in Cash | 2.7m | 9.1m | 1.3m | (15.4m) | 13.4m | (54.4m) | 351.7m |
USD | FY, 2018 |
---|---|
Revenue/Employee | 595.5k |
Debt/Equity | 0.5 x |
Debt/Assets | 0.3 x |
Financial Leverage | 1.8 x |
Y, 2020 | |
---|---|
Male (Senior Management) | 9.2% |
Female (Senior Management) | 7.7% |
Male | 31.8% |
Female | 34.4% |
Y, 2020 | |
---|---|
Hispanic / Latino, percent | 6.9% |
Asian, percent | 20.8% |
White, percent | 59.4% |
Other | 12.9% |